[go: up one dir, main page]

MA48475A - Procédés de fabrication de niraparib - Google Patents

Procédés de fabrication de niraparib

Info

Publication number
MA48475A
MA48475A MA048475A MA48475A MA48475A MA 48475 A MA48475 A MA 48475A MA 048475 A MA048475 A MA 048475A MA 48475 A MA48475 A MA 48475A MA 48475 A MA48475 A MA 48475A
Authority
MA
Morocco
Prior art keywords
niraparib
manufacturing processes
processes
manufacturing
niraparib manufacturing
Prior art date
Application number
MA048475A
Other languages
English (en)
Inventor
Frank Xing Chen
Alistair Stewart
Anthony Joseph Toto
George Wu
Original Assignee
Tesaro Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tesaro Inc filed Critical Tesaro Inc
Publication of MA48475A publication Critical patent/MA48475A/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/26Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C303/00Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides
    • C07C303/32Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of salts of sulfonic acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C303/00Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides
    • C07C303/42Separation; Purification; Stabilisation; Use of additives
    • C07C303/44Separation; Purification
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/70Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D211/74Oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02Boron compounds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02Boron compounds
    • C07F5/025Boronic and borinic acid compounds
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
MA048475A 2017-04-24 2018-04-24 Procédés de fabrication de niraparib MA48475A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762489387P 2017-04-24 2017-04-24
US201762489415P 2017-04-24 2017-04-24

Publications (1)

Publication Number Publication Date
MA48475A true MA48475A (fr) 2020-03-04

Family

ID=63919973

Family Applications (1)

Application Number Title Priority Date Filing Date
MA048475A MA48475A (fr) 2017-04-24 2018-04-24 Procédés de fabrication de niraparib

Country Status (15)

Country Link
US (2) US11161834B2 (fr)
EP (1) EP3615513B1 (fr)
JP (1) JP7179014B2 (fr)
KR (1) KR102582624B1 (fr)
CN (2) CN118271233A (fr)
AU (2) AU2018258274C1 (fr)
CA (1) CA3060715C (fr)
ES (1) ES2926255T3 (fr)
IL (1) IL270068B (fr)
MA (1) MA48475A (fr)
MX (1) MX393879B (fr)
SG (1) SG11201909807TA (fr)
TW (1) TWI783993B (fr)
WO (1) WO2018200517A1 (fr)
ZA (1) ZA201906944B (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3478286B1 (fr) 2016-06-29 2024-01-03 Tesaro, Inc. Méthodes de traitement du cancer de l'ovaire
MX2019011496A (es) 2017-03-27 2020-01-23 Tesaro Inc Composiciones de niraparib.
MA48475A (fr) 2017-04-24 2020-03-04 Tesaro Inc Procédés de fabrication de niraparib
TWI879716B (zh) 2017-05-09 2025-04-11 美商提薩羅有限公司 治療癌症的組合療法
MA49144A (fr) 2017-05-18 2020-03-25 Tesaro Inc Polythérapies pour le traitement du cancer
BR112020006039A2 (pt) 2017-09-26 2020-10-06 Tesaro, Inc. formulações de niraparibe
CA3076515A1 (fr) 2017-09-30 2019-04-04 Tesaro, Inc. Polytherapies pour le traitement du cancer
MA50618A (fr) 2017-10-06 2020-08-12 Tesaro Inc Polyrhérapies et leurs utilisations
EP3860988A1 (fr) 2018-10-03 2021-08-11 Tesaro, Inc. Formes cristallines d'une base libre de niraparib
CN112300074B (zh) * 2019-08-02 2023-12-29 北京盈科瑞创新药物研究有限公司 一种吲唑甲酰胺类化合物及其制备方法和应用
CN119156216A (zh) 2022-02-15 2024-12-17 特沙诺有限公司 尼拉帕尼用于治疗脑癌的用途
WO2024142096A1 (fr) * 2022-12-29 2024-07-04 Dr. Reddy’S Laboratories Limited Procédé de préparation de tosylate de niraparib et de ses intermédiaires
WO2025017711A1 (fr) * 2023-07-20 2025-01-23 Natco Pharma Limited Procédé amélioré pour la préparation de monohydrate de tosylate de niraparib

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5837458A (en) 1994-02-17 1998-11-17 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
US6335160B1 (en) 1995-02-17 2002-01-01 Maxygen, Inc. Methods and compositions for polypeptide engineering
FI104465B (fi) 1995-06-14 2000-02-15 Valio Oy Proteiinihydrolysaatteja allergioiden hoitamiseksi tai estämiseksi, niiden valmistus ja käyttö
EP0987332B1 (fr) 1997-04-23 2009-08-19 Kaneka Corporation ADN codant pour un polypeptide à activité transaminase stéréosélective, et transformants comprenant cet ADN
JP3712255B2 (ja) 1997-12-08 2005-11-02 カリフォルニア・インスティチュート・オブ・テクノロジー ポリヌクレオチドおよびポリペプチド配列を生成するための方法
JP4221100B2 (ja) 1999-01-13 2009-02-12 エルピーダメモリ株式会社 半導体装置
GB0004297D0 (en) 2000-02-23 2000-04-12 Ucb Sa 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses
EP1272967A2 (fr) 2000-03-30 2003-01-08 Maxygen, Inc. Selection de sites de recombinaison par enjambement in silico
EP2272813B1 (fr) 2001-04-24 2016-11-16 Massachusetts Institute of Technology (MIT) Formation de liaisons carbone-oxygène catalysée au cuivre
WO2002100833A1 (fr) 2001-06-12 2002-12-19 Sumitomo Pharmaceuticals Company, Limited Inhibiteurs de rho kinase
KR20070057931A (ko) 2004-09-29 2007-06-07 미쯔비시 웰 파마 가부시키가이샤 타우 단백질 키나아제 1 저해제로서의6-(피리디닐)-4-피리미돈 유도체
JP4611441B2 (ja) 2006-04-03 2011-01-12 イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー ポリ(adp−リボース)ポリメラーゼ(parp)阻害剤としてのアミド置換インダゾール及びベンゾトリアゾール誘導体
CA2661605A1 (fr) 2006-08-31 2008-03-06 Schering Corporation Derives d'hydantoine utiles en tant qu'agents antibacteriens
GEP20115337B (en) 2007-01-10 2011-11-25 St Di Ricerche Di Biologia Molecolare P Angeletti Spa Amide substituted indazoles as poly(adp-ribose)polymerase (parp) inhibitors
WO2008108998A2 (fr) 2007-03-02 2008-09-12 Richmond Chemical Corporation Procédé pour augmenter le rendement et améliorer la purification de produits provenant de réactions avec une transaminase
AR065804A1 (es) * 2007-03-23 2009-07-01 Smithkline Beecham Corp Compuesto de indol carboxamida, composicion farmaceutica que lo comprende y uso de dicho compuesto para preparar un medicamento
EP2152262A2 (fr) 2007-04-27 2010-02-17 UCB Pharma, S.A. Nouveaux dérivés hétérocycliques utilisés pour le traitement de maladies du snc
NZ586675A (en) 2008-01-08 2012-04-27 Merck Sharp & Dohme Pharmaceutically acceptable salts of 2-{ 4-[(3s)-piperidin-3- yl]phenyl} -2h-indazole-7-carboxamide
EP2401366B1 (fr) 2009-02-26 2013-12-18 Codexis, Inc. Biocatalyseurs transaminase
JP2010269667A (ja) 2009-05-20 2010-12-02 Alps Electric Co Ltd 多回転角度検出装置
WO2012024104A2 (fr) 2010-08-16 2012-02-23 Codexis, Inc. Biocatalyseurs et procédés de synthèse de (1r,2r)-2-(3,4-diméthoxyphényléthoxy)cyclohexanamine
PH12013501099A1 (en) 2010-11-30 2013-07-08 Takeda Pharmaceuticals Co Bicyclic compound
KR101638671B1 (ko) 2011-02-08 2016-07-11 화이자 인코포레이티드 글루카곤 수용체 조절자
US8802673B2 (en) 2011-03-24 2014-08-12 Hoffmann-La Roche Inc Heterocyclic amine derivatives
US9073911B2 (en) 2011-06-09 2015-07-07 Hoffmann-La Roche Inc. Pyrazole derivatives
EP3406594A1 (fr) 2012-12-07 2018-11-28 Merck Sharp & Dohme Corp. Procédé de transamination biocatalytique
EP2928473B1 (fr) 2012-12-07 2017-06-28 Merck Sharp & Dohme Corp. Arylation n-2 régiosélective d'indazoles
US20160160294A1 (en) 2014-12-08 2016-06-09 Tesaro Methods and materials for predicting response to niraparib
EP3478286B1 (fr) 2016-06-29 2024-01-03 Tesaro, Inc. Méthodes de traitement du cancer de l'ovaire
CN106496187A (zh) * 2016-09-14 2017-03-15 陕西科技大学 一种制备PARP抑制剂Niraparib的合成方法
CN106432056A (zh) * 2016-09-17 2017-02-22 青岛辰达生物科技有限公司 一种尼拉帕布中间体(3s)‑3‑(4‑氨基苯基)哌啶‑1‑甲酸叔丁酯的制备方法
CN106432057A (zh) * 2016-09-17 2017-02-22 青岛云天生物技术有限公司 一种制备(3s)‑3‑(4‑氨基苯基)哌啶‑1‑甲酸叔丁酯的方法
CN106432055A (zh) * 2016-09-17 2017-02-22 青岛辰达生物科技有限公司 一种尼拉帕布中间体4‑(哌啶‑3‑基)苯胺的制备方法
EP3606523A1 (fr) 2017-03-27 2020-02-12 Tesaro, Inc. Formulations de niraparib
MX2019011496A (es) 2017-03-27 2020-01-23 Tesaro Inc Composiciones de niraparib.
MA48475A (fr) 2017-04-24 2020-03-04 Tesaro Inc Procédés de fabrication de niraparib
TWI879716B (zh) 2017-05-09 2025-04-11 美商提薩羅有限公司 治療癌症的組合療法
MA49144A (fr) 2017-05-18 2020-03-25 Tesaro Inc Polythérapies pour le traitement du cancer
BR112020006039A2 (pt) 2017-09-26 2020-10-06 Tesaro, Inc. formulações de niraparibe
CA3076515A1 (fr) 2017-09-30 2019-04-04 Tesaro, Inc. Polytherapies pour le traitement du cancer
MA50618A (fr) 2017-10-06 2020-08-12 Tesaro Inc Polyrhérapies et leurs utilisations
KR20200105862A (ko) 2017-12-27 2020-09-09 테사로, 인코포레이티드 암을 치료하는 방법
KR20200118117A (ko) 2018-02-05 2020-10-14 테사로, 인코포레이티드 소아용 니라파립 제제 및 소아용 치료 방법

Also Published As

Publication number Publication date
US20200055837A1 (en) 2020-02-20
CN118271233A (zh) 2024-07-02
TWI783993B (zh) 2022-11-21
NZ758948A (en) 2024-04-26
AU2018258274A1 (en) 2019-11-14
AU2021215116A1 (en) 2021-08-26
CA3060715A1 (fr) 2018-11-01
MX393879B (es) 2025-03-24
KR20200021456A (ko) 2020-02-28
WO2018200517A1 (fr) 2018-11-01
AU2021215116B2 (en) 2022-12-01
EP3615513B1 (fr) 2022-07-20
US20220041575A1 (en) 2022-02-10
AU2018258274B2 (en) 2021-05-13
JP2020517668A (ja) 2020-06-18
EP3615513A1 (fr) 2020-03-04
ZA201906944B (en) 2023-03-29
IL270068B (en) 2022-06-01
JP7179014B2 (ja) 2022-11-28
AU2018258274C1 (en) 2021-12-02
CN110753684A (zh) 2020-02-04
KR102582624B1 (ko) 2023-09-22
EP3615513A4 (fr) 2020-12-09
ES2926255T3 (es) 2022-10-24
SG11201909807TA (en) 2019-11-28
CA3060715C (fr) 2024-10-01
BR112019022320A2 (pt) 2020-05-26
US11161834B2 (en) 2021-11-02
US11629137B2 (en) 2023-04-18
TW201841889A (zh) 2018-12-01

Similar Documents

Publication Publication Date Title
MA48475A (fr) Procédés de fabrication de niraparib
MA51792A (fr) Procédés de fabrication de lymphocytes t
DE102016200026B8 (de) Wafer-Herstellungsverfahren
MA43711A (fr) Procédés de production de l-glufosinate
FR3046093B1 (fr) Atelier de fabrication additive
EP3487681A4 (fr) Fabrication additive
EP3383599A4 (fr) Préhenseur de robot
EP3417092C0 (fr) Procédés de fabrication de matériaux en graphène
EP3366271A4 (fr) Procédé de fabrication de film
EP3366270A4 (fr) Procédé de fabrication de film
EP3459684A4 (fr) Robot combiné
EP3551458C0 (fr) Fabrication additive
EP3601418C0 (fr) Procédé de fabrication de panneau recouvert
MA43271A (fr) Formulations améliorées de déférasirox et leurs procédés de fabrication
IL263618A (en) Tracked all-terrain vehicle
EP3679232A4 (fr) Fabrication de panneau de réduction acoustique
EP3663014A4 (fr) Procédé de fabrication de cannettes, et procédé de fabrication de cannettes
EP3694961A4 (fr) Fluides de fabrication
EP3450118A4 (fr) Robot
EP3856438C0 (fr) Procédé de fabrication additive
DK3307216T3 (da) Termoformbare halvstive ortoser
EP3410828A4 (fr) Procédé de fabrication de film
EP3378393A4 (fr) Biocapteur et son procédé de fabrication
EP3644126A4 (fr) Procédé de fabrication ou de régénération
EP3704551C0 (fr) Procédé de production distribuée